NEWS

 

 

 

 

 




Meeting Materials Now Available:
2020 Alliance Spring Virtual Group Meeting

May 8, 2020

The 2020 Alliance Spring Virtual Group Meeting will take place next week May 14-16 utilizing Zoom and Windstream Audio/Video Conferencing.  
 
Meeting materials for the upcoming virtual meeting are now available on the Alliance website. Materials include the spring meeting book, web links/dial-in information/helpfu


FY20 BIQSFP Supplements to Support NRT Integrated Studies to Validate Biomarkers, Imaging Tests, or QOL/PRO Instruments

May 4, 2020

A one-time FY20 opportunity for BIQSFP supplement awards to support non-real time (NRT) integrated studies associated with randomized, phase 2 or 3 trials conducted by NCTN Groups and NCORP Research Bases is currently available.

Up to three supplements will be made by September 30, 2020 and the maximum budget allowed is $500,000 in direct costs per su


New Trial Alert: Alliance A221805 Peripheral Neuropathy Prevention

May 1, 2020

Alliance A221805: Duloxetine to prevent oxaliplatin-Induced chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled phase II to phase III study

Overview: Alliance investigator Ellen M. Lavoie Smith, PhD, RN, FAAN, of the University of Michigan, leads this phase II/III trial to study the best dose of duloxetine and how well it works in preventing pain, tingling, and nu


Older News